Fresenius reaffirms 2026 outlook
Fresenius maintained its 2026 outlook and said Biopharma revenue is targeted to nearly double by 2030 from 2025, with an EBIT margin of around 20%.
1. Outlook and targets
Fresenius maintained its full-year 2026 outlook. It is targeting nearly doubled Biopharma revenue by 2030 compared with 2025, with an EBIT margin of around 20%.
2. Biopharma agreement
An exclusive development agreement with WuXi Biologics gives Fresenius access to up to 37 biosimilar candidates, potentially expanding its portfolio from 29 to 66 molecules over a decade. Fresenius expects to raise its longer-term Biopharma ambitions significantly. Rising development spending will weigh on profitability before products contribute growth, and operating cash flow will fund the agreement without additional debt.
